Buscar
Mostrando ítems 1-10 de 22
Angioplasty stenting with Sirolimus (Rapamycin) eluting stents in type 2 diabetic patients Angioplastia con stents liberadores de rapamicina en diabéticos tipo 2: Experiencia del Hospital DIPRECA
(2007)
Background: Drug-eluting stents have been developed to reduce the rates of restenosis after coronary angioplasty. Several studies have demonstrated that rapamycin eluting stents are reliable and effective. Aim: To report ...
Fundamento e desenho do teste randomizado PAINT
(Sociedade Brasileira de Cardiologia - SBC, 2009-12-01)
BACKGROUND: We describe the rationale and design for the PercutAneous INTervention with biodegradable-polymer based paclitaxel-eluting or sirolimus-eluting versus bare stents for de novo coronary lesions - PAINT trial. ...
Fundamento e desenho do teste randomizado PAINT
(Sociedade Brasileira de Cardiologia - SBC, 2009)
FUNDAMENTO: Descrevemos as bases teóricas e o formato do "Estudo PAINT - Intervenção percutânea com stents com eluição de paclitaxel ou sirolimus em polímero biodegradável comparados com stents sem recobrimento no tratamento ...
Impacto dos stents e do sirolimus por via oral na vasomotilidade coronariana dependente e independente do endotelio
(Sociedade Brasileira de Cardiologia - SBC, 2012-04-01)
BACKGROUND: There is no consensus regarding the impact of stenting on long-term endothelial function. There have been reports of increased endothelial dysfunction with sirolimus-eluting stents as compared to bare metal ...
Impacto dos stents e do sirolimus por via oral na vasomotricidade coronariana dependente e independente do endotélio
(Universidade Federal de São Paulo (UNIFESP), 2012-05-30)
Rationale: There is no consensus regarding the impact of stenting on long-term endothelial function. There have been reports of increased endothelial dysfunction with Sirolimus-eluting stents as compared to bare metal ...
Randomized Evaluation of Two Drug-Eluting Stents With Identical Metallic Platform and Biodegradable Polymer But Different Agents (Paclitaxel or Sirolimus) Compared Against Bare Stents: 1-Year Results of the PAINT Trial
(WILEY-LISS, 2009)
Objectives: We tested two novel drug-eluting stents (DES), covered with a biodegradable-polymer carrier and releasing paclitaxel or sirolimus, which were compared against a bare metal stent (primary objective). The DES ...
Randomized Evaluation of Two Drug-Eluting Stents With Identical Metallic Platform and Biodegradable Polymer But Different Agents (Paclitaxel or Sirolimus) Compared Against Bare Stents: 1-Year Results of the PAINT Trial
(Wiley-Blackwell, 2009-11-01)
Objectives: We tested two novel drug-eluting stents (DES), covered with a biodegradable-polymer carrier and releasing paclitaxel or sirolimus, which were compared against a bare metal stent (primary objective). the DES ...
Late clinical outcomes after implantation of drug-eluting stents coated with biodegradable polymers: 3-year follow-up of the PAINT randomised trial
(EUROPA EDITIONTOULOUSE CEDEX 6, 2012)
Aims: The long-term clinical performance of drug-eluting stents (DES) coated with biodegradable polymers is poorly known. Methods and results: A total of 274 coronary patients were randomly allocated to paclitaxel-eluting ...
One-year performance of thin-strut cobalt chromium sirolimus-eluting stent versus thicker strut stainless Steel biolimus-eluting coronary stent: a propensity-matched analysis of two international all-comers registries
(Lippincott Williams & Wilkins, 2021)
Objectives Recent improvements in coronary stent
design have focussed on thinner struts, different alloys and
architecture, more biocompatible polymers, and shorter
drug absorption times. This study evaluates safety ...